Drugs / SHR-1802
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04414150 | Jun 2020 → Jan 2022 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05794477 | Apr 2023 → Jul 2025 | neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05208177 | Apr 2022 → Aug 2023 | neoplastic disease or syndrome | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05208177 ↗ |
| Modality | Monoclonal antibody | “SHR-1802 is a novel anti-LAG-3 monoclonal antibody.” PMID 37529157 ↗ Jul 2023 |